Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.

    ... BACKGROUND: Lenalidomide is approved for the treatment of anemia with ... death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status ...

    Research Article last updated 08/15/2013 - 9:50am.

  2. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... double-blind study assessed the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International ... 239 patients were randomly assigned (2:1) to treatment with lenalidomide (n = 160) or placebo (n = 79) once per day (on 28-day cycles). The ...

    Research Article last updated 07/18/2016 - 10:30am.

  3. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

    ... April 25, 2013 Lenalidomide is an effective drug in low-risk myelodysplastic syndromes ... on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding ...

    Research Article last updated 07/29/2014 - 8:58am.

  4. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... has been linked to increased sensitivity to the drug lenalidomide . Phase II and III clinical trials have demonstrated the efficacy of lenalidomide in improving clinical outcomes of patients with del(5q) MDS, ...

    Research Article last updated 03/02/2015 - 2:11pm.

  5. I Was Alone With MDS Until I Connected With Others on Social Media

    ... count was so low. I started a regimen of an oral lenalidomide , (Revlimid®). My oncologist then dismissed me without ... counts increased from injections and I continued taking  lenalidomide. I was naïve in thinking lenalidomide would not have side effects ...

    Patient Chronicle last updated 12/12/2017 - 12:06pm.

  6. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

    ... MDS patients achieve an erythroid response with lenalidomide in 25-30% of cases. Addition of erythropoiesis-stimulating ... identified in the diseased clone on response to lenalidomide and the drug effects on clonal evolution remain unknown. We ...

    Research Article last updated 04/29/2016 - 11:33am.

  7. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have ... only in the European Union. Mounting evidence suggests that lenalidomide is effective not only in reducing red blood cell (RBC) ...

    Research Article last updated 12/08/2015 - 1:06pm.

  8. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

    ... treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA ...

    Research Article last updated 04/14/2017 - 9:09am.

  9. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... Introduction: Lenalidomide is an IMiDs? oral immunomodulatory compound developed for the ... syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response may be important to optimize responses and ...

    Research Article last updated 11/16/2011 - 2:10pm.

  10. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

    ... and decreased miR-145 and miR-146a expression. Lenalidomide is an immunomodulatory agent that selectively suppresses the ... of MDM2 with subsequent enhanced P53 degradation. Lenalidomide showed success in low- and intermediate-1-risk MDS as reported in ...

    Research Article last updated 04/17/2014 - 11:29am.